Boston Scientific Corp. stock slipped 0.4% in pre-open trading today as the market continued to digest the company’s Q2 2026 results released two days earlier. The medical device maker posted results that outperformed consensus on both the top and bottom lines, yet it simultaneously reduced its full-year financial outlook for the second consecutive quarter.
For the quarter, Boston Scientific reported revenue of $5.44 billion and adjusted earnings per share of $0.86, both of which came in ahead of analyst expectations. Despite the beats, management cut its 2026 adjusted EPS guidance to a range of $3.28 to $3.32 and trimmed its full-year net sales growth forecast to 5.5% to 6.5%, well below prior projections.
Executives attributed the guidance reset primarily to a sharp and unexpected deceleration in U.S. WATCHMAN stand-alone procedures. According to management, the slowdown has been driven by shifting physician referral patterns and an "ablate and wait" treatment approach following recent clinical trial readouts. In addition, Boston Scientific reported greater-than-anticipated competitive share losses in its electrophysiology - or EP - franchise, a second structural headwind weighing on near-term results.
The market reaction included a broad set of analyst price target reductions that have continued to pressure the stock into today’s session. Raymond James cut its target to $57 from $78, Mizuho reduced its target to $60 from $70, JPMorgan lowered its target to $56 from $80, and Canaccord trimmed its target to $66 from $70. All four firms maintained bullish ratings. Separately, Argus moved to downgrade the shares from Buy to Hold.
Management told investors that the WATCHMAN and EP-related headwinds are expected to persist through 2027, and that a meaningful recovery in revenue and EPS growth is not anticipated until 2028. Those timelines frame investor expectations for an extended period of muted growth in two of the company’s key franchises.
The pressure on Boston Scientific has been company-specific rather than market-driven. On the same trading day, the broader U.S. equity market was positive, with the S&P 500 adding 0.4%, the Dow Jones Industrial Average gaining 0.6%, and the Nasdaq Composite rising 1.2%. The divergence highlights that the stock’s weakness stems from internal operational and procedural dynamics rather than macroeconomic factors.
Shares have also materially retraced from their 52-week high of $109.50 and are now trading closer to the 52-week low of $42.20, reflecting a sustained re-rating of growth prospects following consecutive guidance reductions and renewed competitive pressures.
Taken together, the combination of a second straight downward guidance revision, structural headwinds in WATCHMAN and EP procedures, and a cascade of analyst target cuts has kept the company’s stock under pressure even as broader indices move higher.
Summary
- Boston Scientific beat Q2 consensus with $5.44 billion in revenue and $0.86 adjusted EPS, but trimmed its 2026 adjusted EPS guidance to $3.28–$3.32 and narrowed full-year net sales growth to 5.5%–6.5%.
- Management cited a sharp deceleration in U.S. WATCHMAN stand-alone procedures due to shifting physician referral patterns and an "ablate and wait" approach, plus larger-than-expected EP share losses.
- Analysts have responded with multiple price target cuts and at least one downgrade; management expects WATCHMAN and EP headwinds to persist through 2027 with recovery not expected until 2028.
Key points
- Q2 results beat consensus, but the second consecutive full-year guidance cut has heightened investor concern - impacting the medical devices and healthcare equipment sectors.
- Procedural trends in WATCHMAN and competitive dynamics in electrophysiology are central to near-term revenue and EPS trajectories, influencing investor sentiment across device makers and hospital procedure volumes.
- Analyst reaction was swift, producing several target reductions and at least one downgrade, which adds downward pressure to the stock independent of broad market moves.
Risks and uncertainties
- Persisting declines in WATCHMAN stand-alone procedures could further weigh on U.S. revenue for the company and affect adoption trends in structural heart interventions.
- Continued competitive share losses in the EP franchise may suppress growth and margins for the company and influence competitive dynamics in electrophysiology devices.
- Guidance indicating that headwinds may continue through 2027 introduces uncertainty around near-term financial performance and delays the timeline for recovery to 2028.